ATE353222T1 - Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen - Google Patents
Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagenInfo
- Publication number
- ATE353222T1 ATE353222T1 AT99960187T AT99960187T ATE353222T1 AT E353222 T1 ATE353222 T1 AT E353222T1 AT 99960187 T AT99960187 T AT 99960187T AT 99960187 T AT99960187 T AT 99960187T AT E353222 T1 ATE353222 T1 AT E353222T1
- Authority
- AT
- Austria
- Prior art keywords
- phospholamban
- treatment
- mutant
- molecule
- heart failure
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 102000005681 phospholamban Human genes 0.000 title abstract 2
- 108010059929 phospholamban Proteins 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title 1
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 2
- 108091006112 ATPases Proteins 0.000 abstract 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000000805 cytoplasm Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10671898P | 1998-11-02 | 1998-11-02 | |
US14588399P | 1999-07-27 | 1999-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE353222T1 true ATE353222T1 (de) | 2007-02-15 |
Family
ID=26803944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99960187T ATE353222T1 (de) | 1998-11-02 | 1999-11-02 | Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1126866B1 (de) |
JP (2) | JP2002528512A (de) |
CN (1) | CN1354671A (de) |
AT (1) | ATE353222T1 (de) |
AU (1) | AU1711100A (de) |
CA (1) | CA2349758A1 (de) |
DE (1) | DE69935078T2 (de) |
WO (1) | WO2000025804A2 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7745416B2 (en) * | 1995-04-11 | 2010-06-29 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
DE10027777A1 (de) * | 2000-06-07 | 2001-12-13 | Otogene Ag | Transfektionsverfahren |
ES2320975T3 (es) | 2000-09-11 | 2009-06-01 | The Regents Of The University Of California | Mutante plb dominante negativo para su utilizacion en el tratamiento de enfermedades cardiacas. |
US20040262226A1 (en) * | 2001-08-01 | 2004-12-30 | Atsushi Ikeda | Blood purification apparatus for elevating purification efficiency |
US20050037420A1 (en) * | 2001-09-14 | 2005-02-17 | Mei-Yun Zhang | Immunoglobulin having particular framework scaffold and methods of making and using |
EP1693451B1 (de) * | 2003-11-21 | 2011-11-09 | Daiichi Sankyo Company, Limited | Verfahren zur anzucht von myokardzellen |
EP2801366A3 (de) * | 2004-09-02 | 2015-04-29 | Cognosci, Inc. | Verbesserte ApoE-Analoga und Verwendungsverfahren dafür |
US20060198825A1 (en) * | 2005-03-03 | 2006-09-07 | Kaemmerer William F | Reagents, methods and systems to suppress phospholamban expression |
GB0518027D0 (en) * | 2005-09-05 | 2005-10-12 | Birkeland Innovasjon As | Compounds |
AU2008247564B2 (en) * | 2007-05-02 | 2014-06-05 | Intrexon Corporation | PP1 ligands |
US8221738B2 (en) | 2008-02-19 | 2012-07-17 | Celladon Corporation | Method for enhanced uptake of viral vectors in the myocardium |
US8609813B2 (en) | 2009-06-22 | 2013-12-17 | Health Research Inc. | Prodrug anti-cancer therapy |
CN103865945A (zh) * | 2010-02-10 | 2014-06-18 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Tat核心肽段在制备高效、可溶性表达的外源蛋白中的应用 |
US10208085B2 (en) * | 2012-07-05 | 2019-02-19 | Gwangju Institute Of Science And Technology | Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban |
CN104193826B (zh) * | 2014-09-17 | 2018-02-23 | 山东大学齐鲁医院 | 一种融合多肽及其在制备抗肿瘤药物中的应用 |
CN109890400B (zh) * | 2016-10-24 | 2022-12-20 | 贝特基因公司 | 包含蛋白磷酸酶1抑制肽的血管疾病治疗用组合物 |
CN106831956B (zh) * | 2017-03-29 | 2019-11-08 | 华中科技大学同济医学院附属协和医院 | 一种抗肿瘤多肽mudp-21及其应用 |
CN115354043B (zh) * | 2022-07-08 | 2023-12-08 | 南京大学 | 一种动物模型 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5652122A (en) * | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US6884600B1 (en) * | 1996-03-30 | 2005-04-26 | Medical Research Council London | Protein phosphatase-1 catalytic subunit interactions |
FR2753722A1 (fr) * | 1996-09-26 | 1998-03-27 | Smithkline Beecham Lab | Procede de detection de modulateurs de relaxation cardiaque et modulateurs ainsi obtenus |
US5968959A (en) * | 1997-12-12 | 1999-10-19 | Orion Corporation | Method for the prevention and treatment of stunned myocardium |
-
1999
- 1999-11-02 DE DE69935078T patent/DE69935078T2/de not_active Expired - Lifetime
- 1999-11-02 AT AT99960187T patent/ATE353222T1/de not_active IP Right Cessation
- 1999-11-02 EP EP99960187A patent/EP1126866B1/de not_active Expired - Lifetime
- 1999-11-02 CN CN99815335A patent/CN1354671A/zh active Pending
- 1999-11-02 AU AU17111/00A patent/AU1711100A/en not_active Abandoned
- 1999-11-02 CA CA002349758A patent/CA2349758A1/en not_active Abandoned
- 1999-11-02 JP JP2000579244A patent/JP2002528512A/ja not_active Withdrawn
- 1999-11-02 WO PCT/US1999/025692 patent/WO2000025804A2/en active IP Right Grant
-
2007
- 2007-08-07 JP JP2007204986A patent/JP2008037870A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1354671A (zh) | 2002-06-19 |
EP1126866B1 (de) | 2007-02-07 |
DE69935078D1 (de) | 2007-03-22 |
WO2000025804A9 (en) | 2001-12-06 |
CA2349758A1 (en) | 2000-05-11 |
JP2008037870A (ja) | 2008-02-21 |
AU1711100A (en) | 2000-05-22 |
EP1126866A2 (de) | 2001-08-29 |
JP2002528512A (ja) | 2002-09-03 |
WO2000025804A2 (en) | 2000-05-11 |
WO2000025804A3 (en) | 2000-10-05 |
DE69935078T2 (de) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE353222T1 (de) | Eine mutante phospholamban moleküle und deren verwendung zur behandlung von herzkrankheiten und herzversagen | |
EE200200510A (et) | POL1212 aminohappejärjestust kodeeriv DNA, seda sisaldav ekspressioonivektor, sea modifitseeritud VIII- tegur, sellel põhinev ravimkompositsioon ningmeetod sea modifitseeritud VIII-teguri aminohappejärjestust omava valgu valmistamiseks | |
GEP20043407B (en) | Method of Inhibiting Amyloid Protein Aggregation and Imaging Amyloid Deposits Using Isoindoline Derivatives | |
ATE382364T1 (de) | Von igf-bindungsprotein stammendes peptid | |
CY1107051T1 (el) | Αντι-διηθητικα και αντι-αγγειογενετικα θραυσματα ουροκινασης και η χρηση τους | |
DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
EA200101250A1 (ru) | Предупреждение и терапия амилоидогенного заболевания | |
ES2170104T3 (es) | Inhibidores de la produccion de proteinas de beta-amiloide. | |
PT1200105E (pt) | Factor viii modificado | |
MY162068A (en) | Formulation of human antibodies for treating tnf-(alpha) associated disorders | |
WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
DE60218179D1 (de) | Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern | |
HUP0001293A1 (hu) | Heterociklusos vegyületek és ezeket tartalmazó gyógyászati készítmények béta-amiloid-peptidek gátlására | |
DK0750672T3 (da) | DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse | |
ATE350396T1 (de) | Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung | |
GEP20053423B (en) | Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits | |
ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
DE69534633D1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
ATE344325T1 (de) | Neisseria lactoferrin-bindendes protein | |
DK1506295T3 (da) | Muteiner af placental vækstfaktor type 1, fremstillingsfremgangsmåde og anvendelser deraf | |
TR200103562T2 (tr) | Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri | |
TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
DE69834929D1 (de) | Verwendung eines organspezifischen ernährungmittels | |
DE69712182D1 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
BG106513A (en) | New class of bioactive glycoproteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |